FDA to set up new Office of the Chief Medical Officer as part of agency reshufflingnews2023-12-20T19:22:36+00:00December 20th, 2023|Endpoints News|
Grail has big plans for its blood cancer tests. The first step: Finding a new ownernews2023-12-20T19:00:20+00:00December 20th, 2023|Endpoints News|
Genentech’s food allergy medication gets priority review nod from the FDAnews2023-12-20T18:49:39+00:00December 20th, 2023|Endpoints News|
FDA encourages collaboration between monoclonal antibody sponsors to keep pace with emerging Covid variantsnews2023-12-20T18:14:38+00:00December 20th, 2023|Endpoints News|
Biotech and pharma 2023 winners and losers listnews2023-12-20T16:15:10+00:00December 20th, 2023|Endpoints News|
Passage Bio scraps a therapy; XOMA’s new loan; Impel is for salenews2023-12-20T15:36:29+00:00December 20th, 2023|Endpoints News|
Scoop: Resilience downsizes technical R&D and quality assurance divisionsnews2023-12-20T15:03:15+00:00December 20th, 2023|Endpoints News|
GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfrontnews2023-12-20T12:34:15+00:00December 20th, 2023|Endpoints News|
Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidatesnews2023-12-20T12:30:46+00:00December 20th, 2023|Endpoints News|
Argenx abandons pemphigus program after Vyvgart Hytrulo fails PhIII trialnews2023-12-20T12:26:44+00:00December 20th, 2023|Endpoints News|
